Radiosensitizing Glioblastoma in a Rat Model Using L-Buthionine-SR-Sulfoximine (BSO)
Studies have shown that malignant tumors have a high content of glutathione an antioxidant responsible for protecting the cells against damage from free radicals (mainly superoxide, hydroxyl and hydrogen peroxide). It is well established that glutathione, by neutralizing these free radicals plays a major role in radioresistance. Glioblastoma has relatively high levels of glutathione. In this study, by reducing the glutathione content of glioblastoma in a rat model, we were able to investigate the effect of this reduction in enhancing the effect of radiotherapy as a form of treatment for glioblastoma multiforme in a rat model.
By injecting L-Buthionine-SR-Sulfoximine (BSO) in to the tumor tissue, the glutathione content of the tumor was reduced by about 70% of its initial value. When administered into the tumors 2 hours prior to radiotherapy the animals so treated had a significantly longer median survival time compared with animals that received radiotherapy alone.
Advisor:Griebel, Robert; Juurlink , Bernhard; Keith, Roger; Vachhrajani, Haresh; Fourney, Daryl; McFadden, Andy; Chapman, Dean
School:University of Saskatchewan
School Location:Canada - Saskatchewan
Source Type:Master's Thesis
Keywords:l buthionine sr sulfoximine rat glioblastoma radiosensitizer radiotherapy glutathione c6 glioma cell line bso
Date of Publication:04/21/2008